FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065206445> ?p ?o ?g. }

• W2065206445 abstract "BACKGROUND Fibrin generation during and after therapy with alteplase may depend on the level of concomitant anticoagulation. The hypothesis that fibrinopeptide A (FPA) levels, as markers of ongoing in vivo fibrin formation, correlate with the angiographic and clinical outcome of thrombolysis is tested. METHODS AND RESULTS Serial plasma FPA levels were determined in 334 patients of the randomized European Cooperative Study Group trial comparing heparin versus placebo plus alteplase and aspirin in patients with acute myocardial infarction. Median FPA levels (with the 10th to 90th percentiles) were 21 ng/ml (2-390 ng/ml) before treatment in placebo-allocated patients (n = 166) and increased to 49 (15-580), 34 (4-320), 27 (2-240), 29 (2-430), and 30 (3-390) ng/ml after 0.75, 3, 12, 24, and 36 hours, respectively. In heparin-allocated patients (n = 168), median baseline FPA values were 18 ng/ml (2-210 ng/ml) and decreased to 6 (1-110), 5 (1-75), 5 (1-60), 7 (1-100), and 10 (1-170) ng/ml at corresponding time points (p less than 0.0001 for the difference at each time point). Adequate anticoagulation, defined as no activated partial thromboplastin time value below twice the pretreatment value at 3, 12, 24, and 36 hours after initiation of treatment, was obtained in 48 patients assigned to heparin. It was associated with normal median FPA levels (less than or equal to 4 ng/ml) at all time points compared with 12 (2-80), 16 (2-240), and 15 (2-240) ng/ml at 12, 24, and 36 hours, respectively, in heparin-assigned but inadequately anticoagulated patients (n = 102, p less than 0.001 for each time point). In the heparin-treated group, median FPA values tended to be lower at all time points in patients with patent vessels than in patients with occluded arteries, but the difference was significant only at 24 hours (p = 0.04). FPA levels did not correlate with clinically apparent recurrent ischemia or with left ventricular thrombosis on two-dimensional echocardiography. CONCLUSIONS During and after thrombolytic therapy with alteplase, the enhanced fibrin generation is suppressed by sustained concomitant anticoagulation with intravenous heparin. Adequate anticoagulation warrants individual titration of the heparin dose. High plasma FPA levels 24 hours after alteplase therapy are specific but insensitive markers of vessel occlusion in anticoagulated patients. They do not correlate with clinical outcome." @default.
• W2065206445 created "2016-06-24" @default.
• W2065206445 creator A5001446916 @default.
• W2065206445 creator A5003479425 @default.
• W2065206445 creator A5005657208 @default.
• W2065206445 creator A5023982501 @default.
• W2065206445 creator A5034824935 @default.
• W2065206445 creator A5046978879 @default.
• W2065206445 creator A5049260728 @default.
• W2065206445 date "1992-03-01" @default.
• W2065206445 modified "2023-10-16" @default.
• W2065206445 title "Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group." @default.
• W2065206445 cites W1533600198 @default.
• W2065206445 cites W1970046651 @default.
• W2065206445 cites W1977967610 @default.
• W2065206445 cites W1982207241 @default.
• W2065206445 cites W1986774920 @default.
• W2065206445 cites W2002575736 @default.
• W2065206445 cites W2013846566 @default.
• W2065206445 cites W2014500899 @default.
• W2065206445 cites W2026550457 @default.
• W2065206445 cites W2027593484 @default.
• W2065206445 cites W2029847463 @default.
• W2065206445 cites W2030328556 @default.
• W2065206445 cites W2064328001 @default.
• W2065206445 cites W2072747756 @default.
• W2065206445 cites W2078324852 @default.
• W2065206445 cites W2082595502 @default.
• W2065206445 cites W2113166567 @default.
• W2065206445 cites W2150595619 @default.
• W2065206445 cites W2164771213 @default.
• W2065206445 cites W2169518571 @default.
• W2065206445 cites W2211305637 @default.
• W2065206445 cites W2329761741 @default.
• W2065206445 cites W2337057096 @default.
• W2065206445 cites W2409296984 @default.
• W2065206445 cites W2411548274 @default.
• W2065206445 cites W2444248115 @default.
• W2065206445 cites W3170680033 @default.
• W2065206445 cites W4235858444 @default.
• W2065206445 cites W4250713935 @default.
• W2065206445 doi "https://doi.org/10.1161/01.cir.85.3.928" @default.
• W2065206445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1537129" @default.
• W2065206445 hasPublicationYear "1992" @default.
• W2065206445 type Work @default.
• W2065206445 sameAs 2065206445 @default.
• W2065206445 citedByCount "79" @default.
• W2065206445 crossrefType "journal-article" @default.
• W2065206445 hasAuthorship W2065206445A5001446916 @default.
• W2065206445 hasAuthorship W2065206445A5003479425 @default.
• W2065206445 hasAuthorship W2065206445A5005657208 @default.
• W2065206445 hasAuthorship W2065206445A5023982501 @default.
• W2065206445 hasAuthorship W2065206445A5034824935 @default.
• W2065206445 hasAuthorship W2065206445A5046978879 @default.
• W2065206445 hasAuthorship W2065206445A5049260728 @default.
• W2065206445 hasBestOaLocation W20652064451 @default.
• W2065206445 hasConcept C126322002 @default.
• W2065206445 hasConcept C142724271 @default.
• W2065206445 hasConcept C164705383 @default.
• W2065206445 hasConcept C203014093 @default.
• W2065206445 hasConcept C204787440 @default.
• W2065206445 hasConcept C27081682 @default.
• W2065206445 hasConcept C2776820930 @default.
• W2065206445 hasConcept C2776825266 @default.
• W2065206445 hasConcept C2777557582 @default.
• W2065206445 hasConcept C2777628954 @default.
• W2065206445 hasConcept C2778213512 @default.
• W2065206445 hasConcept C2778261982 @default.
• W2065206445 hasConcept C2778382381 @default.
• W2065206445 hasConcept C2779384505 @default.
• W2065206445 hasConcept C2779581417 @default.
• W2065206445 hasConcept C42219234 @default.
• W2065206445 hasConcept C500558357 @default.
• W2065206445 hasConcept C54173615 @default.
• W2065206445 hasConcept C71924100 @default.
• W2065206445 hasConceptScore W2065206445C126322002 @default.
• W2065206445 hasConceptScore W2065206445C142724271 @default.
• W2065206445 hasConceptScore W2065206445C164705383 @default.
• W2065206445 hasConceptScore W2065206445C203014093 @default.
• W2065206445 hasConceptScore W2065206445C204787440 @default.
• W2065206445 hasConceptScore W2065206445C27081682 @default.
• W2065206445 hasConceptScore W2065206445C2776820930 @default.
• W2065206445 hasConceptScore W2065206445C2776825266 @default.
• W2065206445 hasConceptScore W2065206445C2777557582 @default.
• W2065206445 hasConceptScore W2065206445C2777628954 @default.
• W2065206445 hasConceptScore W2065206445C2778213512 @default.
• W2065206445 hasConceptScore W2065206445C2778261982 @default.
• W2065206445 hasConceptScore W2065206445C2778382381 @default.
• W2065206445 hasConceptScore W2065206445C2779384505 @default.
• W2065206445 hasConceptScore W2065206445C2779581417 @default.
• W2065206445 hasConceptScore W2065206445C42219234 @default.
• W2065206445 hasConceptScore W2065206445C500558357 @default.
• W2065206445 hasConceptScore W2065206445C54173615 @default.
• W2065206445 hasConceptScore W2065206445C71924100 @default.
• W2065206445 hasLocation W20652064451 @default.
• W2065206445 hasLocation W20652064452 @default.
• W2065206445 hasOpenAccess W2065206445 @default.
• W2065206445 hasPrimaryLocation W20652064451 @default.
• W2065206445 hasRelatedWork W194959292 @default.
• W2065206445 hasRelatedWork W2027664694 @default.

• next